

Special Issue

Vaccines Against Swine Respiratory Diseases

Message from the Guest Editor

Porcine respiratory disease complex (PRDC) is a multifaceted illness caused by a mix of viral and bacterial pathogens, environmental conditions, and management practices. Several key pathogens are associated with PRDC, including porcine circovirus 2 (PCV2), porcine reproductive and respiratory syndrome virus (PRRSV), and mycoplasma. Several other pathogens have been linked to PRDC, such as PCV3, PCV4, the swine influenza virus (SIV), porcine respiratory coronavirus (PRCV), porcine cytomegalovirus (PCMV), porcine parainfluenza virus 1 (PPV1), and swine orthopneumovirus (SOV). With regard to bacteria, *Actinobacillus pleuropneumoniae*, *Glasserella parasuis*, and *Bordetella bronchiseptica* have been implicated. Swine farming practices have evolved, resulting in a higher density, which has led to a higher prevalence of PRDC. In response, substantial efforts are being made to improve and develop new vaccine platforms. The goal of this Special Issue is to collate original research focused on the development and evaluation of vaccines for PRDC. We welcome the submission of original research articles and reviews.

Guest Editor

Prof. Dr. Jairo Jaime

Animal Health Department, Center of Infectious Diseases and Veterinary Immunology, College of Veterinary Medicine and Production Animal, Colombia National University, Bogotá, Colombia

Deadline for manuscript submissions

31 May 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/248846

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).